Exploring how the locus coeruleus affects attention in healthy adults
Investigation of Locus Coeruleus Function in Sustained Attention
PHASE4 · University of California, Davis · NCT06041048
This study is testing how a part of the brain called the locus coeruleus affects attention in healthy adults, using special imaging techniques and a medication to see if it makes a difference.
Quick facts
| Phase | PHASE4 |
|---|---|
| Study type | Interventional |
| Enrollment | 40 (estimated) |
| Ages | 18 Years to 60 Years |
| Sex | All |
| Sponsor | University of California, Davis (other) |
| Locations | 1 site (Sacramento, California) |
| Trial ID | NCT06041048 on ClinicalTrials.gov |
What this trial studies
This study aims to investigate the function of the locus coeruleus (LC), a brain region involved in attention and cognitive processes, by developing advanced imaging techniques to measure its activity. Using high-resolution magnetic resonance imaging (MRI) tailored for the brainstem, the researchers will assess the LC's role in sustained attention and goal-directed behavior. The study will also involve pharmacological manipulation with modafinil to confirm the functional activity of the LC. By improving methods to measure LC activity, the research seeks to enhance understanding of attentional control and its implications for mental health disorders.
Who should consider this trial
Good fit: Ideal candidates for this study are healthy adults aged 18 to 60 who are typically developing.
Not a fit: Patients with a history of schizophrenia, psychosis, or significant neurological disorders may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could lead to better understanding and treatment strategies for attention-related disorders.
How similar studies have performed: While studies have explored the locus coeruleus's role in attention, this approach using advanced imaging techniques is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Between the ages of 18 - 60 years of age, * Typically developing, healthy adult Exclusion Criteria: * History of schizophrenia, other forms of psychosis, * Specific or focal neurological disorder or severe alcohol or drug use disorder within the past 5 years * History of left ventricular hypertrophy or in patients with mitral valve prolapse who have experienced the mitral valve prolapse syndrome when previously receiving CNS stimulants, or who have had recent history of myocardial infarction or unstable angina. * Volunteers with known hypersensitivity to modafinil or armodafinil or its inactive ingredients * Known allergy/sensitivity or any hypersensitivity to components of modafinil or its formulation * Inability to swallow tablets or tolerate oral medication; * Pregnant or nursing (participants will be required to have a negative pregnancy test) * Contraindication for MRI scanning (metal implants, pacemakers, metal foreign bodies, or pregnancy) * Use of psychotropic medication within the past week * Claustrophobic and not comfortable being in a small space may also not want to participate
Where this trial is running
Sacramento, California
- University of California, Davis — Sacramento, California, United States (RECRUITING)
Study contacts
- Study coordinator: Julie Schweitzer, PhD
- Email: jschweitzer@ucdavis.edu
- Phone: 9167030450
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Attention - no Condition is Being Assessed - Healthy Adults